Alzheimer's Drug Discovery Foundation | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Senicapoc in Alzheimer's Disease	Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Recruiting	Phase 2	2026-08-17		NCT04804241
METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia	Cognition Disorders, Cognitive Decline, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, psychiatric disorder	Active, not recruiting	Phase 2	2026-07-10		NCT05109169
Nabilone for Agitation Blinded Intervention Trial	Alzheimer disease, Chemically-Induced Disorders, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, cannabis dependence, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, substance-related disorder, tauopathy	Recruiting	Phase 3	2026-01-28		NCT04516057
Effects of Brain Beta-Amyloid on Postoperative Cognition	Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Cognitive Complications, Postoperative Complications, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Active, not recruiting	Phase 4	2025-05-01		NCT01606488